Diseases of the Colon & Rectum

, Volume 37, Supplement 2, pp S16–S23 | Cite as

Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I

  • Fiorella Guadagni
  • Mario Roselli
  • Maurizio Cosimelli
  • Antonella Spila
  • Francesco Cavaliere
  • Raffaella Arcuri
  • Maria Rosaria Abbolito
  • John W. Greiner
  • Jeffrey Schlom
Original Contributions


Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.

Key words

Tumor antigen Monoclonal antibody Colorectal carcinoma Serum marker Antigen phenotype 


  1. 1.
    Wanebo HJ, Rao B, Pinsky CM,et al. Preoperative carcinoembryonic antigen levels as a prognostic indicator of colorectal cancer. N Engl J Med 1978;299:448–51.PubMedGoogle Scholar
  2. 2.
    Wood CB, Ratcliffe JG, Burt RW, Malcolm AJ, Blumgast LH. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg 1980;67:47–8.Google Scholar
  3. 3.
    Szymendera JJ, Nowacki MP, Szawlowski AW, Kamiska JA. Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 1982;25:46–52.PubMedGoogle Scholar
  4. 4.
    Goldenberg DM, Neville AM, Cortes AC, Go VL, Holyoke ED, Issellbacher KJ. Carcinoembryonic antigen: its role as a marker in the management of cancer: a National Institute of Health Consensus Development Conference. Ann Intern Med 1987;94:407–9.Google Scholar
  5. 5.
    Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 1988;12:321–55.PubMedGoogle Scholar
  6. 6.
    Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199–3203.PubMedGoogle Scholar
  7. 7.
    Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850–7.PubMedGoogle Scholar
  8. 8.
    Thor A, Ohuchi N, Szpak CA, Johnston W, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118–24.PubMedGoogle Scholar
  9. 9.
    Thor A, Viglione MJ, Muraro R, Ohuchi N, Schlom J, Gorstein F. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissue. Int J Gynecol Pathol 1987;6:235–47.PubMedGoogle Scholar
  10. 10.
    Xu M, Real FX, Welt S, Schussler MH, Oettgen HF, Old LJ. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer 1989;44:985–9.PubMedGoogle Scholar
  11. 11.
    Muraro R, Kuroki D, Wunderlich D,et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588–96.PubMedGoogle Scholar
  12. 12.
    Gero EJ, Colcher D, Ferroni P,et al. The CA 72.4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients. J Clin Lab Anal 1989;3:360–9.PubMedGoogle Scholar
  13. 13.
    Ohuchi N, Takahashi K, Matoba N,et al. Comparison of serum assay for TAG-72, CA19.9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989;19:242–8.PubMedGoogle Scholar
  14. 14.
    Guadagni F, Roselli M, Amato T,et al. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma: a longitudinal study. Cancer 1991;11:2443–50.Google Scholar
  15. 15.
    Guadagni F, Roselli M, Amato T,et al. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res 1992;52:1222–7.PubMedGoogle Scholar
  16. 16.
    Guadagni F, Roselli M, Cosimelli M,et al. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to CEA in monitoring colorectal cancer patients. Cancer 1993;72:2098–2106.PubMedGoogle Scholar
  17. 17.
    Ohuchi N, Simpson JF, Colcher D, Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer 1987;40:726–33.PubMedGoogle Scholar
  18. 18.
    Simpson JF, Primus F, Schlom J. Complementation of expression of carcinoembryonic antigen and tumor assisted glycoprotein-72 (TAG-72) in human colon adenocarcinomas. J Biol Mark 1991;6:83–90.Google Scholar
  19. 19.
    Au FC, Stein B, Tang CK. Carcinoembryonic antigen levels in colonic lesions. Am J Surg 1986;151:61–4.PubMedGoogle Scholar
  20. 20.
    Cooper HS, Cox J, Patchefsky AS. Immunohistologic study of blood group substances in polyps of the distal colon. Expression of a fetal antigen. Am J Clin Pathol 1980;73:345–50.PubMedGoogle Scholar
  21. 21.
    Enblad P, Busch C, Carlsson E,et al. The adenomacarcinoma sequence in rectal adenomas. Support by expression of blood group substances and carcinoma antigens. Am J Clin Pathol 1988;89:121–30.Google Scholar
  22. 22.
    Itzkowitz SH, Yuan M, Ferrell LD,et al. Cancer-associated alterations of blood group antigen expression in human colorectal polyps. Cancer Res 1986;46:5976–84.PubMedGoogle Scholar
  23. 23.
    O'Brien MJ, Zamcheck N, Burke B,et al. Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value. Am J Clin Pathol 1981;75:283–90.PubMedGoogle Scholar
  24. 24.
    Johnston WW, Szpaok CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 1985;45:1894–1900.PubMedGoogle Scholar
  25. 25.
    Johnston WW, Szpaok CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as a novel immunocytochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. Hum Pathol 1986;17:501–13.PubMedGoogle Scholar
  26. 26.
    Szpak CA, Johnston WW, Roggli V,et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252–60.PubMedGoogle Scholar
  27. 27.
    Wolf RC, D'Emilia JC, Salem RR,et al. Detection of the tumor associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon. J Natl Cancer Inst 1989;81:1913–7.PubMedGoogle Scholar
  28. 28.
    Stramignoni D, Bowen R, Atkinson BF, Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983;31:543–52.PubMedGoogle Scholar
  29. 29.
    Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988;48:3597–4603.Google Scholar
  30. 30.
    Colcher D, Milenic DE, Ferroni P,et al.In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 1990;31:1133–42.PubMedGoogle Scholar
  31. 31.
    Schlom J, Colcher D, Roselli M,et al. Tumor targeting with monoclonal antibody B72.3. Nucl Med Biol 1989;16:137–42.Google Scholar
  32. 32.
    Martin DT, Hinkle GH, Tuttle S,et al. Intraoperative radioimmunodetection of colorectal tumor with a hand-held radiation detector. Am J Surg 1985;150:672–5.PubMedGoogle Scholar
  33. 33.
    Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C,et al. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 1987;30:761–4.PubMedGoogle Scholar
  34. 34.
    Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990;50:1291–8.PubMedGoogle Scholar

Copyright information

© American Society of Colon and Rectal Surgeons 1994

Authors and Affiliations

  • Fiorella Guadagni
    • 1
  • Mario Roselli
    • 2
  • Maurizio Cosimelli
    • 1
  • Antonella Spila
    • 1
  • Francesco Cavaliere
    • 1
  • Raffaella Arcuri
    • 1
  • Maria Rosaria Abbolito
    • 1
  • John W. Greiner
    • 3
  • Jeffrey Schlom
    • 3
  1. 1.Regina Elena Cancer InstituteRomeItaly
  2. 2.Department of SurgeryUniversity of Rome Tor VergataRomeItaly
  3. 3.Laboratory of Tumor Immunology and BiologyNational Cancer InstituteBethesda

Personalised recommendations